Biography
Professional Summary
Education & Certifications
- Residency: UCSF Dept of Internal Medicine (2013) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2017) CA
- Medical Education: Stanford University School of Medicine (2010) CA
-
- Fellowship, Stanford University Hospital, Oncology/Hematology (2017)
- Residency, University of California, San Francisco (UCSF), Internal Medicine (2013)
- MPH, Harvard School of Public Health (2010)
- MD, Stanford School of Medicine (2010)
- BSE, Duke University (2004)
Honors & Awards
- US Fulbright Scholar, South Korea (2005)
-
Publications
-
In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., Ai, W. Z., … Levy, R. (2012). In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. BLOOD, 119(2), 355–63. -
Consolidative Radiotherapy in Metastatic Urothelial Cancer.
Shah, S., Zhang, C. A., Hancock, S., Fan, A., Skinner, E., & Srinivas, S. (2017). Consolidative Radiotherapy in Metastatic Urothelial Cancer. Clinical Genitourinary Cancer. -
The CD47 Macrophage Checkpoint as a New Immunotherapy Target
Sikic, B. I., Padda, S. K., Shah, S. A., Colevas, D., Narayanan, S., Fisher, G. A., … Weissman, I. L. (2017). The CD47 Macrophage Checkpoint as a New Immunotherapy Target. JOURNAL OF THORACIC ONCOLOGY. ELSEVIER SCIENCE INC. -
-
Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B. I., … Cheng, I. (2018). Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population. Journal of the National Comprehensive Cancer Network : JNCCN, 16(11), 1353–60. -
First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers.
Sikic, B. I., Lakhani, N., Patnaik, A., Shah, S. A., Chandana, S. R., Rasco, D., … Padda, S. K. (2019). First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO1802018. -
Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study
Changa, N. M., Xie, W., Bilen, M. A., Dzimitrowicz, H., Burkart, J., Geynisman, D. M., … Harshman, L. C. (2019). Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. LANCET ONCOLOGY, 20(4), 581–90. -
Prognostic factors for pancreatic metastases in renal cell cancer.
Chung, A., Li, S., Shah, S., Fan, A. C., & Srinivas, S. (2016). Prognostic factors for pancreatic metastases in renal cell cancer. JOURNAL OF CLINICAL ONCOLOGY, 34(15). -
Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC).
Chanza, N. M., Xie, W., Issa, M., Dzimitrowicz, H. E., Tripathi, A., Beuselinck, B., … Harshman, L. C. (2019). Retrospective analysis of the safety and efficacy of immune checkpoint inhibitors (CPI) among patients (pts) with pre-existing autoimmune disorders (AD) and renal cell carcinoma (RCC) or urothelial carcinoma (UC). JOURNAL OF CLINICAL ONCOLOGY, 37(15). -
Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.
Martinez Chanza, N., Xie, W., Issa, M., Dzimitrowicz, H., Tripathi, A., Beuselinck, B., … C Harshman, L. (2020). Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study. Journal for Immunotherapy of Cancer, 8(1). -
Feasibility and design of a cloud-based digital platform in patients with advanced cancer.
Roy, M., Hall, E. T., Velazquez, B., Shah, S., Fardeen, T., Cunanan, K., … Ramchandran, K. (2019). Feasibility and design of a cloud-based digital platform in patients with advanced cancer. JOURNAL OF CLINICAL ONCOLOGY, 37(27). -
Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California.
DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., … Cheng, I. (2020). Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California. Cancer Causes & Control : CCC. -
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., … Warner, J. L. (2020). Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet (London, England). -
Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer.
Bhambhvani, H. P., Zamora, A., Shkolyar, E., Prado, K., Greenberg, D. R., Kasman, A. M., … Shah, J. B. (2020). Development of robust artificial neural networks for prediction of 5-year survival in bladder cancer. Urologic Oncology. -
Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study.
Rivera, D. R., Peters, S., Panagiotou, O. A., Shah, D. P., Kuderer, N. M., Hsu, C.-Y., … Warner, J. L. (2020). Utilization of COVID-19 treatments and clinical outcomes among patients with cancer: A COVID-19 and Cancer Consortium (CCC19) cohort study. Cancer Discovery. -
Remote Oncology Care: Review of Current Technology and Future Directions
McGregor, B. A., Vidal, G. A., Shah, S. A., Mitchell, J. D., & Hendifar, A. E. (2020). Remote Oncology Care: Review of Current Technology and Future Directions. CUREUS, 12(8). -
DEVELOPING THE ADVANCED PRACTICE ROLE IN INFUSION TREATMENT AREA
Shah, D., Kuriakose, C., Healy, D., & Shah, S. (2020). DEVELOPING THE ADVANCED PRACTICE ROLE IN INFUSION TREATMENT AREA. ONCOLOGY NURSING FORUM, 47(2). -
Remote Oncology Care: Review of Current Technology and Future Directions.
McGregor, B. A., Vidal, G. A., Shah, S. A., Mitchell, J. D., & Hendifar, A. E. (2020). Remote Oncology Care: Review of Current Technology and Future Directions. Cureus, 12(8), e10156. -
Association of renal cell carcinoma subtypes with race/ethnicity and comorbid medical conditions
Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B., Shah, S. A., … Cheng, I. (2020). Association of renal cell carcinoma subtypes with race/ethnicity and comorbid medical conditions. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 29(6). -
Testicular cancer in Hispanics: Incidence of subtypes over time according to neighborhood sociodemographic factors in California
DeRouen, M. C., McKinley, M., Shah, S. A., Borno, H. T., Aoki, R., Lichtensztajn, D. Y., … Cheng, I. (2020). Testicular cancer in Hispanics: Incidence of subtypes over time according to neighborhood sociodemographic factors in California. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 29(6). -
Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California.
Wu, J. T.-Y., Kwon, D. H., Glover, M. J., Henry, S., Wood, D., Rubin, D. L., … Shah, S. A. (2020). Changes in Cancer Management due to COVID-19 Illness in Patients with Cancer in Northern California. JCO Oncology Practice, OP2000790. -
Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study.
Bhambhvani, H. P., Greenberg, D. R., Kasman, A. M., DeRouen, M. C., Cheng, I., Eisenberg, M. L., & Shah, S. A. (2021). Racial and socioeconomic disparities in retroperitoneal lymph node dissection and survival in nonseminomatous germ cell tumor: A population-based study. Urologic Oncology. -
Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19)
Rubinstein, S., Grivas, P., Choueiri, T. K., Kuderer, N. M., Shah, D., Rivera, D. R., … Rini, B. I. (2020). Clinical impact of COVID-19 on patients with cancer: Data from the COVID-19 and Cancer Consortium (CCC19). JOURNAL OF CLINICAL ONCOLOGY, 38(18). -
PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., … Iagaru, A. (2021). PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. -
Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors.
Waliany, S., Neal, J. W., Reddy, S., Wakelee, H., Shah, S. A., Srinivas, S., … Zhu, H. (2021). Myocarditis Surveillance with High-Sensitivity Troponin I During Cancer Treatment with Immune Checkpoint Inhibitors. JACC. CardioOncology, 3(1), 137–39. -
Reply to R. Kebudi et al.
Tsu-Yu Wu, J., Kwon, D. H., Glover, M., Henry, S., Wood, D., Rubin, D., … Shah, S. A. (2021). Reply to R. Kebudi et al. JCO Oncology Practice, OP2100105. -
Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population
Lichtensztajn, D. Y., Leppert, J. T., Brooks, J. D., Shah, S. A., Sieh, W., Chung, B., … Cheng, I. (2018). Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 16(11), 1353–1360. -
Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer.
Generalova, O., Roy, M., Hall, E., Shah, S. A., Cunanan, K., Fardeen, T., … Ramchandran, K. (2021). Implementation of a cloud-based electronic patient-reported outcome (ePRO) platform in patients with advanced cancer. Journal of Patient-Reported Outcomes, 5(1), 91. -
Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer
Gupta, D., Fardeen, T., Teuteberg, W., Seevaratnam, B., Asuncion, M. K., Alves, N., … Ramchandran, K. (2021). Use of a computer model and care coaches to increase advance care planning conversations for patients with metastatic cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Patterns in cancer management changes for patients with COVID-19 in northern California.
Glover, M., Wu, J., Kwon, D. H., Zhang, S., Henry, S., Wood, D., … Shah, S. (2021). Patterns in cancer management changes for patients with COVID-19 in northern California. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin, V. S., Henderson, N., James, M., Natesan, D., Freeman, D., Nizam, A., … Alva, A. S. (2021). Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer. -
Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States.
Hawley, J. E., Sun, T., Chism, D. D., Duma, N., Fu, J. C., Gatson, N. T., … Hwang, C. (1800). Assessment of Regional Variability in COVID-19 Outcomes Among Patients With Cancer in the United States. JAMA Network Open, 5(1), e2142046. -
Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study.
Satyanarayana, G., Enriquez, K. T., Sun, T., Klein, E. J., Abidi, M., Advani, S. M., … Farmakiotis, D. (2022). Coinfections in Patients With Cancer and COVID-19: A COVID-19 and Cancer Consortium (CCC19) Study. Open Forum Infectious Diseases, 9(3), ofac037. -
Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis.
Rubinstein, S. M., Bhutani, D., Lynch, R. C., Hsu, C.-Y., Shyr, Y., Advani, S., … Thompson, M. A. (2022). Patients recently treated for B-lymphoid malignancies show increased risk of severe COVID-19: a CCC19 registry analysis. Blood Cancer Discovery. -
Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population.
Chiang, R. S., Ashok, A., Mauer, E., Barrett, A., Hoerner, C. R., Khan, O. A., … Khaki, A. R. (2022). Association of renal cell carcinoma (RCC) metastatic to pancreas with a distinct molecular profile and immune cell population. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
The Will to Go On.
Shah, S. (2022). The Will to Go On. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, JCO2201188. -
Characterization of remote second-opinion oncology patients and associated changes in management.
Shah, A. P., Shi, S., & Shah, S. (2022). Characterization of remote second-opinion oncology patients and associated changes in management. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
COVID-19 in patients with gynecologic cancer: A preliminary report from the COVID-19 and Cancer Consortium (CCC19).
Beeghly-Fadiel, A., Prescott, L. S., Ruiz-Garcia, E., Hwang, C., Heilman, H., Mckay, R. R., … Brown, A. J. (2022). COVID-19 in patients with gynecologic cancer: A preliminary report from the COVID-19 and Cancer Consortium (CCC19). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Post-acute sequelae of SARS-CoV-2 infection in patients with cancer.
Warner, J. L., Pinato, D. J. J., Mishra, S., Saliby, R. M., Hwang, C., Gulati, S., … Shah, D. P. (2022). Post-acute sequelae of SARS-CoV-2 infection in patients with cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19.
Bakouny, Z., Labaki, C., Grover, P., Awosika, J., Gulati, S., Hsu, C.-Y. Y., … Wise-Draper, T. M. (2022). Interplay of Immunosuppression and Immunotherapy Among Patients With Cancer and COVID-19. JAMA Oncology. -
Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer.
Gensheimer, M. F., Gupta, D., Patel, M. I., Fardeen, T., Hildebrand, R., Teuteberg, W., … Ramchandran, K. (2022). Use of Machine Learning and Lay Care Coaches to Increase Advance Care Planning Conversations for Patients With Metastatic Cancer. JCO Oncology Practice, OP2200128. -
Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population.
Lichtensztajn, D. Y., Hofer, B. M., Leppert, J. T., Brooks, J. D., Chung, B. I., Shah, S. A., … Cheng, I. (2022). Associations of Renal Cell Carcinoma Subtype with Patient Demographics, Comorbidities, and Neighborhood Socioeconomic Status in the California Population. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology. -
In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity.
Molina, G. E., Schwartz, B., Srinivas, S., Shah, S., & Zaba, L. C. (2023). In Patients with Advanced Urothelial Carcinoma, Immune Checkpoint Inhibition Prior to Enfortumab Vedotin Is Associated with High-grade Skin Toxicity. European Urology. -
Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma.
Johnson, D. B., Atkins, M. B., Hennessy, C., Wise-Draper, T., Heilman, H., Awosika, J., … Warner, J. L. (2023). Impact of COVID-19 in patients on active melanoma therapy and with history of melanoma. BMC Cancer, 23(1), 265. -
COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease.
Moey, M. Y., Hennessy, C., French, B., Warner, J. L., Tucker, M. D., Hausrath, D. J., … Nohria, A. (2023). COVID-19 severity and cardiovascular outcomes in SARS-CoV-2-infected patients with cancer and cardiovascular disease. Translational Oncology, 34, 101709. -
Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes
Glover, M., Chiang, R. S., Hoerner, C. R., Khan, O. A., Kao, C.-S., Shah, S., … Khaki, A. R. (2023). Renal cell carcinoma with metastasis to the pancreas: Genomic signatures and clinical outcomes. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis
Kommalapati, A., Laliotis, G., Glover, M., Selig, G., Kollipara, R., Mahmood, T., … Tan, A. (2023). Association of tumor-informed minimal residual disease (MRD) with clinical outcomes for muscle invasive bladder cancer (MIBC): A multicenter retrospective real-world analysis. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, T., Zhang, L., Jiang, C., Kilari, D., Alhalabi, O., Nizam, A., … Koshkin, V. S. (2023). Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer.
Khaki, A. R., Fan, A. C., Shah, S., Parikh, D. A., Chien, J., Moore, K., … Srinivas, S. (2023). Phase 2 open label study of durvalumab with neoadjuvant chemotherapy in variant histology bladder cancer. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC).
Koshkin, V. S., Henderson, N., Kilari, D., Jindal, T., Alhalabi, O., Freeman, D., … Alva, A. S. (2023). Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (pts) with advanced urothelial carcinoma (aUC). JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study.
Jindal, T., Kilari, D., Alhalabi, O., Nizam, A., Khaki, A. R., Basu, A., … Koshkin, V. S. (2023). Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program.
Parikh, D. A., Rodriguez, G. M., Ragavan, M., Kerr, E., Asuncion, M. K., Hansen, J., … Patel, M. I. (2024). Lay healthcare worker financial toxicity intervention: a pilot financial toxicity screening and referral program. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 32(3), 161. -
Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., … Iagaru, A. (2024). Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. -
Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning: A Randomized Clinical Trial.
Rodriguez, G. M., Parikh, D. A., Kapphahn, K., Gupta, D. M., Fan, A. C., Shah, S., … Patel, M. I. (2024). Coaches Activating, Reaching, and Engaging Patients to Engage in Advance Care Planning: A Randomized Clinical Trial. JAMA Oncology. -
Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer.
Sfakianos, J. P., Basu, A., Laliotis, G., Cumarasamy, S., Rich, J. M., Kommalapati, A., … Galsky, M. D. (2024). Association of Tumor-informed Circulating Tumor DNA Detectability Before and After Radical Cystectomy with Disease-free Survival in Patients with Bladder Cancer. European Urology Oncology. -
Real-world implementation of an EHR-integrated, SMS text remote patient monitoring platform at an academic cancer center
Shah, S., Kadurugamuwa, G., Tisch, A. H., Lu, M., Modarresi, S., Johnston, C., & Colbert, J. (2024). Real-world implementation of an EHR-integrated, SMS text remote patient monitoring platform at an academic cancer center. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study.
Jiang, C. Y., Jindal, T., Epstein, I. B., Nguyen, C. B., Nizam, A., Bakaloudi, D. R., … Campbell, M. T. (2024). Efficacy of erdafitinib in FGFR2/3-altered metastatic urothelial cancer including patients with CDK2NA/B or MTAP loss: Analysis of UNITE study. JOURNAL OF CLINICAL ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS.
-
Undertreatment of High-Risk Localized Prostate Cancer in the California Latino Population.
Clinical Trials
Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.
Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.
Practice Locations
Urologic Cancer Program in Palo Alto Palo Alto, CA
Palo Alto, CAUrologic Cancer Program in Palo Alto
875 Blake Wilbur Dr
Palo Alto , CA 94304
Make An Appointment More Clinic Information Getting HereUrologic Cancer Program in San Jose San Jose, CA
San Jose, CAUrologic Cancer Program in San Jose
2589 Samaritan Dr
San Jose , CA 95124
Make An Appointment More Clinic Information Getting HereMedical Oncology Program in South Bay San Jose, CA
San Jose, CAMedical Oncology Program in South Bay
2589 Samaritan Dr
San Jose , CA 95124
Make An Appointment More Clinic Information Getting HereCancer Center in South Bay San Jose, CA
San Jose, CACancer Center in South Bay
2589 Samaritan Dr
San Jose , CA 95124
Make An Appointment More Clinic Information Getting HereImportant Information about Our Organizations and Physician Affiliation
Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are each independent nonprofit organizations that are affiliated with but separate from each other and from Stanford University. The physicians who provide care at facilities operated by Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners are faculty, foundation, or community physicians who are not employees, representatives, or agents of Stanford Health Care, Stanford Health Care Tri- Valley, or Stanford Medicine Partners. Stanford Health Care, Stanford Health Care Tri-Valley, and Stanford Medicine Partners do not exercise control over the care provided by such faculty, foundation, and community physicians and are not responsible for their actions.
Patient Reviews
(395 reviews)
View More Patient Reviews
Referring Physicians
PHYSICIAN HELPLINE
Fax: 650-320-9443
Monday–Friday, 8 a.m.–5 p.m.
Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. For help with all referral needs and questions, visit Referral Information.
You may also submit a web referral or complete a referral form and fax it to 650-320-9443 or email the Referral Center at ReferralCenter@stanfordhealthcare.org.
- Send referrals online
- Place radiology and lab orders
- View referral status
- Access medical records